SGN-30 (Seattle genetics).
Article Details
- CitationCopy to clipboard
Schnell R, Borchmann P
SGN-30 (Seattle genetics).
Curr Opin Mol Ther. 2006 Apr;8(2):164-72.
- PubMed ID
- 16610770 [ View in PubMed]
- Abstract
Seattle Genetics is developing SGN-30, an intravenously administered recombinant anti-CD30 monoclonal antibody for the potential treatment of Hodgkin's disease, certain non-Hodgkin's lymphomas, specific leukemia, and immunological diseases such as multiple sclerosis and systemic lupus erythematosus. Phase II trials in patients with Hodgkin's disease, anaplastic large cell lymphoma, and cutaneous lymphoma have been conducted in the U.S. and Europe.
DrugBank Data that Cites this Article
- Drugs